Argenx Stock Soars on Positive VYVGART Hytrulo Trial
5d ago·0:00 listen·Source: Pluang
Summary
Argenx stock is up following positive Phase 3 trial results. The company's drug, VYVGART Hytrulo, showed success in treating autoimmune myositis. This is especially good news for patients with IMNM, who currently have no approved therapies. The trial met its primary endpoint with statistically significant results. This development could offer a new treatment option for those living with this condition.
Read the full article on Pluang →
This is an AI-generated audio summary. Always check the original source for complete reporting.